NIFTY NINE IN NINETY NINE PLUS ONE Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : NIFTY NINE IN NINETY NINE PLUS ONE

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Linda Pearson who wrote (329)	2/1/1999 5:08:00 PM
From: Arthur Radley	of 613

Linda, I'm sorry that you thought I was "slamming" Scios, if you follow many of my post you will find that I'm a big supporter of the biotech industry. For my pocketbook and the good of mankind/womankind, I hope every biotech has great success in bringing new drugs to the market. The observation I made about SCIO was based on the article which has been referenced for you and which I clearly stated in my earlier post and when it states the FDA panel... "narrowly voted to recommend Natrecor as a short-term intravenous treatment" and further states..."several analysts said Natrecor will face tough sledding in a market already filled with treatment options", I'm still inclined to say that this information isn't "upbeat".(:>)

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next